Niacin
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | Niacin (vitamin B3) — nicotinic acid and nicotinamide |
|---|---|
| Chemical class | Pyridine carboxylic acid (nicotinic acid) and its amide (nicotinamide); NAD/NADP precursors |
| CAS | 59-67-6 (nicotinic acid) · 98-92-0 (nicotinamide) |
| Primary source | Basil leaf (Ocimum spp.) for botanical grades; chemical synthesis for isolated grades |
| Key applications | NAD and NADP coenzyme supply, energy metabolism, DNA repair, lipid metabolism at pharmacological dose |
| Claim strength | High for pellagra and deficiency; High for lipid modification; null for cardiovascular outcomes on a statin |
| Typical form | Botanical concentrate at declared assay, or crystalline nicotinic acid / nicotinamide |
| Buy from Herbuno | Niacin 3.6% from Basil Leaf · Liposomal Vitamin B3 |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot; phytosanitary on request |
Name origin: Niacin is a deliberate contraction of nicotinic acid plus in, coined in the 1940s specifically so that flour fortification would not appear to involve nicotine. The compound is unrelated to the tobacco alkaloid beyond a shared pyridine ring and a shared oxidation origin. It remains one of the few nutrients renamed for marketing reasons, and the rename worked.
Traditional use and discovery: The relevant history is pellagra, and it is a case study in how a dietary practice carries knowledge that a transplanted crop loses. Maize contains niacin in a bound form, niacytin, that humans cannot absorb. Mesoamerican cultures processed maize with lime or wood ash — nixtamalisation — which releases it. When maize spread to Europe, Africa and the American South without the processing method, pellagra followed: dermatitis, diarrhoea, dementia and death. Joseph Goldberger demonstrated in the 1910s that it was dietary rather than infectious, against considerable institutional resistance, and Conrad Elvehjem identified nicotinic acid as the preventive factor in 1937.
Research trajectory: After deficiency was solved by fortification, niacin took an unusual second life as the first drug shown to modify blood lipids, from the 1950s. It raises HDL cholesterol and lowers triglycerides and lipoprotein(a) more effectively than most agents. That pharmacology sustained decades of cardiovascular use until two large outcome trials in the statin era tested whether those lipid changes translated into fewer events. They did not, and niacin's cardiovascular role largely collapsed. More recently the field has moved to NAD precursor biology, where nicotinamide riboside and nicotinamide mononucleotide are the active research compounds.
Commercial source: Isolated niacin is synthesised, typically by oxidation of alkyl pyridines, and supplied as crystalline nicotinic acid or nicotinamide. Botanical niacin is extracted from plant material that accumulates it — basil leaf in our case — and standardised to a declared percentage. Because niacin doses are in the tens of milligrams for nutritional use, botanical grades are formulable; at the hundreds-of-milligrams pharmacological doses used for lipids, they are not.
Evidence for Niacin Applications
The cardiovascular case failed, and formulators should know this before positioning a product. AIM-HIGH and HPS2-THRIVE both tested niacin added to statin therapy in large populations. Neither showed a reduction in cardiovascular events despite niacin doing exactly what it was expected to do to the lipid panel — raising HDL, lowering triglycerides. HPS2-THRIVE additionally reported excess serious adverse events in the niacin arm, including disturbances of diabetes control, infection and bleeding. This is one of the clearest demonstrations available that a favourable lipid change is not the same as a clinical benefit. Claim strength: High for the null result.
Pellagra prevention and deficiency correction remain unambiguous. Niacin deficiency produces the classic triad of photosensitive dermatitis, diarrhoea and dementia, progressing to death if untreated, and it responds rapidly to repletion. It persists today in populations dependent on unprocessed maize or sorghum, in chronic alcohol use, in malabsorptive disease and in carcinoid syndrome where tryptophan is diverted. Since the body converts tryptophan to niacin at roughly 60 to 1, protein-adequate diets rarely produce deficiency, which is why fortification largely solved it. Claim strength: High.
Nicotinic acid and nicotinamide are not interchangeable and the difference matters commercially. Both serve as NAD precursors and both correct deficiency. Only nicotinic acid causes the flush, and only nicotinic acid has the lipid-modifying activity, because the lipid effect runs through a receptor that nicotinamide does not engage. Nicotinamide also does not cause flushing, making it the usual choice in multivitamins and cosmetics. A product using nicotinamide and implying lipid benefit is making a claim its chosen form cannot deliver. Claim strength: High.
The flush is prostaglandin-mediated, harmless and commercially fatal if unmanaged. Nicotinic acid triggers cutaneous prostaglandin D2 release, producing intense warmth, redness and itching across the face and upper body within fifteen to thirty minutes, lasting up to an hour. It alarms users, who frequently discontinue. Tolerance develops with consistent daily dosing, and aspirin taken beforehand blunts it. Extended-release forms reduce it — but the sustained-release formats developed to minimise flushing carry a documented hepatotoxicity risk that immediate-release niacin does not, which is a genuine trade-off rather than an improvement. Claim strength: High.
NAD precursor research is the active frontier and is not a niacin claim. Interest in NAD decline with age has driven attention to nicotinamide riboside and nicotinamide mononucleotide, which raise NAD by different routes with different efficiency. Human trials show these raise blood NAD reliably; demonstrations of functional benefit in healthy people are preliminary and endpoints vary. Plain niacin and nicotinamide are cheaper NAD precursors, which is sometimes used to position them within this narrative. The honest statement is that the NAD field is promising and immature, and that results from one precursor do not transfer to another. Claim strength: Emerging.
Upper limits for niacin are set on flushing rather than toxicity, which creates confusion. The US tolerable upper intake level is 35 milligrams daily and EFSA sets 10 milligrams for nicotinic acid, both derived from the flush threshold rather than organ harm. Meanwhile pharmacological lipid doses run 1,000 to 2,000 milligrams, fifty times the upper limit, under medical supervision. At those doses hepatotoxicity, hyperglycaemia and hyperuricaemia are real. A supplement should sit on the nutritional side of that gap and not blur it. Claim strength: High.
Sourcing niacin from Herbuno. Our botanical grade is Niacin 3.6% from Basil Leaf, standardised to declared assay, suited to nutritional-dose clean-label formulation. A liposomal vitamin B3 powder is available for delivery-format work.
Specify which form your application needs — nicotinic acid for flush-dependent or lipid positioning, nicotinamide for flush-free multivitamin and topical use — since they are not interchangeable. All lots ship with CoA and MSDS as standard; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
Niacin is declared as niacin equivalents in nutritional labelling, where one milligram NE equals one milligram of niacin or sixty milligrams of dietary tryptophan. For supplement formulation you are dosing the compound directly. Adult RDA is 16 milligrams NE for men and 14 for women. Our botanical concentrate at 3.6% delivers 36 milligrams of niacin per gram of extract, so a 16 milligram nutritional dose requires around 450 milligrams of material — formulable in a capsule, but not alongside much else. Pharmacological lipid doses of 1,000 milligrams and up are not achievable by the botanical route at all.
Form selection should be driven by whether you want the flush. Nicotinic acid flushes and carries the lipid activity; nicotinamide does neither. Inositol hexanicotinate is marketed as flush-free niacin, but it releases free nicotinic acid poorly and has not demonstrated the lipid effects of nicotinic acid, so it tends to deliver neither the flush nor the benefit. Extended-release nicotinic acid reduces flushing but carries hepatotoxicity risk absent from immediate-release material, and that trade-off should be an explicit decision rather than a default.
Both forms are chemically robust in formulation — stable to heat, light and a wide pH range, and more forgiving than most B vitamins in processing. Nicotinic acid is mildly acidic and poorly soluble in cold water; nicotinamide is considerably more soluble, which is why it dominates in liquids, effervescents and topical cosmetic formulations. Neither contributes significant taste at nutritional doses. For botanical grades the plant matrix contributes bulk and colour that should be assessed in the finished format before the inclusion rate is locked.
For analytical control, specify the form explicitly on the purchase specification, since nicotinic acid and nicotinamide are routinely conflated under the single word niacin and a certificate stating only "niacin" is ambiguous. Assay by HPLC with UV detection. For botanical grades, require source species and plant part, extraction solvent and residual solvent limits. Heavy metals should run on the same certificate for plant-derived material. India-origin botanical material ships with phytosanitary certification on request alongside CoA and MSDS.
Frequently Asked Questions — Niacin
Does niacin prevent heart attacks?
No, on the evidence from AIM-HIGH and HPS2-THRIVE. Both added niacin to statin therapy in large populations and neither reduced cardiovascular events, despite niacin raising HDL and lowering triglycerides as expected. HPS2-THRIVE also found excess serious adverse events in the niacin arm. It is one of the clearest available demonstrations that moving a lipid marker is not the same as improving an outcome.
What causes the niacin flush and should I avoid it?
Nicotinic acid triggers cutaneous prostaglandin D2 release, producing warmth, redness and itching within fifteen to thirty minutes. It is harmless but alarming, and it is the main reason users quit. Tolerance builds with consistent dosing. Note the trade-off: sustained-release forms reduce flushing but carry a hepatotoxicity risk that immediate-release niacin does not.
Nicotinic acid or nicotinamide — which should I use?
Nicotinamide for multivitamins and topicals, since it does not flush. Nicotinic acid if you need the lipid activity, which runs through a receptor nicotinamide does not engage. Both correct deficiency equally. A product using nicotinamide while implying lipid benefit is claiming something its chosen form cannot deliver.
Is flush-free niacin a good option?
Inositol hexanicotinate is the usual flush-free product, and the problem is that it releases free nicotinic acid poorly. It tends to deliver neither the flush nor the lipid effect. If you want flush-free, nicotinamide is the more honest route, provided you are not making lipid claims.
How much basil leaf extract gives a nutritional dose?
Around 450 mg for a 16 mg niacin dose, since the extract is standardised to 3.6%. That is formulable in a capsule but leaves limited room for other actives. Pharmacological lipid doses of 1,000 mg and above are not achievable by the botanical route — that is synthetic territory.
Why source niacin from India?
About 80% of raw nutraceutical ingredients originate in China and a qualified second origin is increasingly a continuity requirement rather than a price exercise. For botanical niacin, basil is an Indian crop with established cultivation and extraction capacity, so the provenance story and the supply-security case point the same way.